MANNKIND CORP (MNKD)

Company Profile

MannKind Corp. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic products and devices for those with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 391 full-time employees. The company went IPO on 2004-07-28. The firm is focused on the development and commercialization of therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The firm's technologies, Technosphere dry-powder formulations and Dreamboat inhalation devices offer convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The firm's products are Afrezza (insulin human) Inhalation Powder, and V-Go wearable insulin delivery device. Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. V-Go wearable insulin delivery device provides continuous subcutaneous infusion of insulin in adults that require insulin.

Company Info

MANNKIND CORP

1 Casper Street

Danbury CONNECTICUT 91362

P: 18186615000

CEO: Michael E. Castagna

Employees: 391

Website: https://mannkindcorp.com/